Resource

 

 

 

 

 

 

 

 

 

 

 

Greenberg Traurig Germany advises Tristan on the sale of a logistics portfolio in Germany and Austria

19 Feb 2018

Greenberg Traurig Germany advised CCP IV Core Plus-Style Fund (CCP IV) and European Property Investors Special Opportunities III (EPISO 3) on the sale of a logistics portfolio in Germany and Austria. The two funds are managed by the real estate company Tristan Capital Partners. The buyer is Frasers Property Investment Europe, a subsidiary of Frasers Property listed on the Singapore Stock Exchange. The purchase price amounts to approximately EUR 178 million.

Prior Scientific acquires Elektron Technology’s Queensgate Nano Business

19 Feb 2018

National law firm Mills & Reeve have advised Cambridge based Prior Scientific Instruments on its acquisition of the Queensgate Nano business from Electron Technology.

Prior Scientific is a global leader in the design and manufacture of precision positioning devices, optical systems, automation solutions, and components with offices in Cambridge, the US, Germany, Japan and China.

Orrick Advises Deutsche Telekom on Creation of U.S./Germany Smart Glasses Joint Venture with ZEISS

16 Feb 2018

Deutsch: Orrick berät Deutsche Telekom bei Gründung eines deutsch-amerikanischen Smart Glasses Joint Ventures mit ZEISS

Orrick advised Deutsche Telekom on the creation of a joint venture with the ZEISS Group for the development of innovative smart glasses.

The company, tooz technologies, is based in the U.S. and Germany. Equally funded, the company assumes strategic and operational responsibility for the further evolution of the optical technology invented by ZEISS, and the delay-free connectivity provided by Telekom.

Ropes & Gray Advises Harbin Pharmaceutical in a $300 Million Strategic Investment and China Joint Venture with GNC Holdings, Inc.

16 Feb 2018

Ropes & Gray is advising Harbin Pharmaceutical Group Holding Co., Ltd, a leading pharmaceutical company in China, in a strategic investment of approximately $300 million in GNC Holdings, Inc. Upon closing, it will become the single largest shareholder in GNC.

In addition, GNC and Harbin Pharmaceutical have agreed to form a joint venture for the manufacturing, marketing, sale and distribution of GNC-branded products in China. The transaction is expected to close in the second half of 2018, subject to customary closing conditions.